Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Eli Lilly’s weight loss drug Zepbound outperformed competitor Novo Nordisk’s Wegovy, according to a clinical trial funded by Lilly. The SURMOUNT-5 trial, a Phase 3b open-label clinical trial ...

Caremark stood to receive substantial fees for the weight-loss drugs even without excluding Zepbound. Novo Nordisk and Eli Lilly have a duopoly in the booming market for weight-loss drugs ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Zepbound Beats Wegovy for Weight Loss in First Head-To-Head Trial of Blockbuster Drugs People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo ...

Zepbound and Wegovy were compared in a head-to-head trial to show which weight loss drug was more effective for patients. This trial consisted of 751 people in the U.S. who were overweight or ...

Weight loss was about 6% lower in men than in ... or list of covered drugs, as of July 1. Zepbound will be excluded. It's important to have a range of drugs to treat a disease as widespread ...